1. 1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC). (September 2015) Authors: Miles, D.; Cameron, D.; Bondarenko, I.; Lyudmila, M.; Alcedo, J.C.; Lopez, R.I.; Im, S.A.; Canon, J.L.; Shparyk, Y.; Yardley, D.; Masuda, N.; Ro, J.; Hubeaux, S.; Quah, C.; Bais, C.; O'Shaughnessy, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗